| Keywords: |
clinical trial; cisplatin; fluorouracil; cancer risk; diarrhea; monotherapy; pyridines; note; united states; capecitabine; drug megadose; antineoplastic agent; colorectal cancer; adenocarcinoma; cancer susceptibility; metastasis; antimetabolites, antineoplastic; antineoplastic combined chemotherapy protocols; drug administration schedule; obesity; smoking; editorial; combination chemotherapy; continuous infusion; cancer research; cancer mortality; docetaxel; irinotecan; europe; diet; drug combination; dosage schedule comparison; folinic acid; stomach cancer; epirubicin; platinum derivative; taxane derivative; drug administration; drug combinations; drug dose regimen; administration, oral; antineoplastic antimetabolite; infusions, intravenous; stomach neoplasms; fluoropyrimidine; united kingdom; esophagus carcinoma; clinical trials; intravenous drug administration; stomach tumor; pyridine derivative; oral drug administration; tegafur; helicobacter infection; 5 chloro 2,4 dihydroxypyridine plus oxonate potassium plus tegafur; oxonic acid; oxonate potassium; s 1 (combination)
|
